This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
OLIG2 / Oligodendrocyte transcription factor 2 · Western blot design guide
Design a Western Blot for OLIG2
Real validated OLIG2 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-OLIG2 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Evidence assembled September 2026 · For research use; verify linked source records and product datasheet before use
OLIG2 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | ~32.4 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Cerebellum (IHC candidate; verify WB) +4 more | |
| Negative control | Adipose tissue (IHC candidate; verify WB) |
Important caveats
Reasons your observed band may differ from the expected size.
| PTM | — | |
| Caveat | Blocking peptide control | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 1 isoform(s) |
Section 1
Real Curated OLIG2 Western Blot Protocols
The A02247-1 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | EL4 cell lysate (catalog A02247-1) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | Western blot analysis of OLIG2 in EL4 cell lysate with OLIG2 antibody at 1 μg/ml in (A) the absence and (B) the presence of blocking peptide (catalog A02247-1) |
| Primary antibody | A02247-1 · 1 μg/ml (catalog A02247-1) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
Section 2
What Is the Expected OLIG2 Western Blot Band Size?
OLIG2 is predicted at 32.4 kDa; no empirical band size is supplied, and the listed features do not demonstrate altered migration.
| Single band near 32.4 kDa | Consistent with the predicted OLIG2 mass |
| Band above 32.4 kDa | Its identity or altered migration needs confirmation |
| Band below 32.4 kDa | Its identity or sample integrity needs confirmation |
| Multiple bands | The supplied UniProt features do not establish distinct OLIG2 sizes |
💡Expected OLIG2 appearanceUniProt predicts OLIG2 at 32.4 kDa, but no empirical band size is supplied; confirm a candidate band with a blocking peptide or independent antibody.
| UniProt predicted mass | Sets the full-length reference size near 32.4 kDa |
| Predicted molecular weight of 32,385 Da | Corresponds to approximately 32.4 kDa |
| Predicted full-length size | Does not establish an empirical migration position |
| UniProt mass reference | Provides no demonstrated explanation for a size difference |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Nuclear OLIG2 may be poorly recovered | Check nuclear extraction and sample loading |
| Band higher than expected | The higher band's identity is uncertain | Compare blocking-peptide and independent-antibody controls |
| Band lower than expected | The lower band's identity or sample integrity is uncertain | Check sample integrity and use an independent antibody |
| Broad smear instead of sharp band | The supplied features do not establish a cause | Check sample quality and compare antibody controls |
| Multiple bands | The supplied features do not establish multiple OLIG2 sizes | Use blocking-peptide or independent-antibody controls |
| Weak or no signal | OLIG2 abundance or recovery may be low | Check a suitable positive sample and nuclear extraction |
Experiment evidence
Western blot images showing OLIG2 band
A02247-1 · OLIG2
A02247-2 · OLIG2
M02247 · OLIG2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for OLIG2 Western blot
🧪HPA-IHC candidate guidance (verify in WB): For positive controls for OLIG2 in Western blot, you can use cerebellum tissue, where HPA reports high expression.
Positive control: Cerebellum (IHC candidate; verify WB)
Negative control: Adipose tissue (IHC candidate; verify WB)
Loading controls: Run GAPDH, β-actin, and a total-protein stain alongside the samples.
⚠️Feasibility: OLIG2 is nuclear, so a nuclear extract may improve detection.
HPA tissue expression evidence for OLIG2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Higher expression tissues · candidate positive controls from IHC
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebellum | granular cells - nucleus | High | Protein (IHC) | HPA → |
| Caudate | glial cells | Medium | Protein (IHC) | HPA → |
| Cerebral cortex | glial cells | Medium | Protein (IHC) | HPA → |
| Hippocampus | glial cells | Medium | Protein (IHC) | HPA → |
| Placenta | cytotrophoblasts | Medium | Protein (IHC) | HPA → |
Lower expression tissues · IHC evidence, not confirmed WB-negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced OLIG2 Western Blot Tips
Deeper troubleshooting and optimisation questions for OLIG2, answered from its protein features.
Where should the OLIG2 band appear?
Band shift · The supplied sequence predicts 32.4 kDa for the 323-residue protein. Use this as a reference, not a guaranteed apparent band position; no observed band size is supplied.
Could an annotated isoform explain a second band?
Isoforms · Only one isoform is listed, with no alternative sequence. The supplied features do not support assigning a second band to a specific OLIG2 isoform.
Do annotated modifications explain an OLIG2 band shift?
PTM · This record lists no modified residues or glycosylation sites. It therefore does not identify a modification responsible for a shifted band. A size difference alone cannot establish a modification.
Does this guide establish induction of OLIG2?
Induction · No general induction response is established by this guide. A pathway or gene-set association is not evidence of induction in a particular specimen. Verify the relevant treatment and control in a target-specific experiment.
How should transfer be checked for OLIG2?
Transfer · Standard workflow guidance: verify transfer efficiency for the intended target size before interpreting a weak signal. Use total-protein assessment and optimize transfer for the membrane, gel and apparatus; the labelled catalog values take precedence.
How should blocking be optimized?
Blocking · Standard workflow guidance: follow the A02247-1 datasheet where specified. Otherwise compare 5% milk or 5% BSA in TBST; for a phospho-specific assay start with BSA. Optimize background and specific signal with matched controls.
How should OLIG2 be quantified across fractions?
Quantitation · Because OLIG2 is annotated in both nucleus and cytoplasm, quantify the same identified OLIG2 band consistently in each fraction. A change in one fraction may reflect altered localization rather than a change in total OLIG2.
Which cell fraction should be checked for OLIG2?
Interpretation · OLIG2 is annotated in both the nucleus and cytoplasm. Its bHLH-domain nuclear localization signal may be masked, and interaction with a partner or NKX2-2 may mediate nuclear entry. Check both fractions when assessing localization.
OLIG2 interacts with NKX2-2 and ZNF488. Those interactions alone do not establish that a higher Western-blot band contains a stable OLIG2 complex; verify the band's identity before assigning it.
Compare them with the 32.4 kDa predicted mass, but do not assign their identity from position alone. This record provides no observed band size, alternative isoform sequence, or annotated modification that identifies an additional band.
OLIG2 interacts with NKX2-2 and ZNF488. Those interactions alone do not establish that a higher Western-blot band contains a stable OLIG2 complex; verify the band's identity before assigning it.
Compare them with the 32.4 kDa predicted mass, but do not assign their identity from position alone. This record provides no observed band size, alternative isoform sequence, or annotated modification that identifies an additional band.
Boster reagents
OLIG2 Western Blot Antibodies
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Real WB data
Anti-OLIG2 Antibody
Cat # A02247-1
Real WB data
Anti-OLIG2 Antibody Picoband®
Cat # A02247-2
Real WB data
Anti-Olig2 Rabbit Monoclonal Antibody
Cat # M02247
All three anti-OLIG2 antibodies list human, mouse, and rat reactivity and include Western blot images. The captions show specific samples and conditions, not broad validation across tissues. A02247-2 and M02247 report bands above the stated 32 kDa expected size.
Which to pick: For documented human, rat, and mouse samples, consider A02247-2 (THP-1, brain, Neuro-2a) or M02247 (HEL, brain). A02247-1 shows EL4 lysate with a blocking-peptide comparison. Match the example to your sample and check the reported band size.
Source: BosterBio OLIG2 gene-info card — filtered to Western-blot-capable antibodies; each card shows that product's actual WB validation figure.
References
- UniProt Consortium. UniProt entry Q13516.
- Human Protein Atlas. OLIG2 tissue expression.
- PMC8032681 — target-verified WB comparison
- PMC10060425 — target-verified WB comparison
- PMC3861791 — target-verified WB comparison